CNS Pharmaceuticals, Inc. 8-K

What Happened

• CNS Pharmaceuticals, Inc. announced a private placement (Securities Purchase Agreement) with institutional investors on May 4, 2026, expected to close on May 5, 2026, that will generate gross proceeds of approximately $22.5 million. The offering includes 650,000 shares of common stock at $2.30 per share and pre-funded warrants to purchase 9,143,479 shares at $2.299 each.
• The company also reported a board change: Jerzy (George) Gumulka resigned from the board on May 4, 2026, and the board appointed Michal Fisher as an independent director the same day.

Key Details

• Offering size and price: 650,000 common shares at $2.30 each; 9,143,479 pre-funded warrants at $2.299 each; gross proceeds ≈ $22.5M (before fees/expenses).
• Pre-Funded Warrants: exercisable immediately for one share at $0.001 per share; exercise limited so a holder cannot exceed 4.99% (or up to 9.99% if elected) of outstanding common stock after exercise. Warrants expire when fully exercised.
• Registration & resale: Company agreed to file a registration statement to register resale of the issued securities within 15 days after closing and to use best efforts to have it declared effective within 60 days of filing (90 days if the SEC reviews).
• Restrictions & fees: Securities sold in a Regulation D private placement (unregistered). Placement agent A.G.P./Alliance Global Partners will receive a cash fee equal to 7.0% of gross proceeds plus reimbursement of certain expenses (up to $75,000 and $15,000 for non-accountable expenses).
• Use of proceeds: Net proceeds intended for identifying, acquiring and advancing new assets, and for working capital and general corporate purposes.
• Board appointment: Michal Fisher, a senior life sciences executive with 15+ years in business development, corporate strategy, and capital raising, was appointed as an independent director and will receive the company’s standard non-employee director compensation; no related-person transactions were reported.

Why It Matters

• Dilution and capitalization: The issuance of shares and immediate exercisable pre-funded warrants will increase the company’s outstanding shares once exercised, which can dilute existing shareholders; exercise limitations protect against any single investor exceeding a specified ownership threshold.
• Funding and strategy: The financing provides CNS roughly $22.5M in gross capital to pursue acquisitions and advance assets, which may accelerate corporate strategy but changes the company’s capital structure.
• Share liquidity and regulatory timing: The company will register the resale of these securities soon after closing, which will enable resale in the public market once the registration statement is effective.
• Corporate governance: The board change brings new business-development and capital-raising experience (Michal Fisher) to the board, which may affect strategic and partnership efforts going forward.

Keywords: private placement, pre-funded warrants, dilution, registration rights, board appointment, capital raise, CNS Pharmaceuticals.